Overall, these results are encouraging, but they require experimental validation and additional preclinical studies to clarify the mechanisms associated with ERβ activation and define an effective and safe dose that supports its possible repositioning as a therapeutic alternative for BC. The gene discussed is ESR2; the disease is breast cancer.